In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: Major effects on CYPs 2B6, 2C8, 2C9 and 2C19

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 4, 2013, Pages 362-371

  Xu, Cong ^a   Desta, Zeruesenay ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral agents; Cytochrome P450; Drug drug interaction; Quantitative prediction; Reversible inhibition; Time dependent inhibition

Indexed keywords

AMODIAQUINE; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; EFAVIRENZ; MEPHENYTOIN; METHADONE; OMEPRAZOLE; PHENYTOIN; PROGUANIL; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE;

ANTI-RETROVIRAL AGENTS; AREA UNDER CURVE; BENZOXAZINES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MICROSOMES, LIVER; PRODRUGS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84883166941     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RG-124     Document Type: Article

References (58)

1. Deeks, E. D. and Perry, C. M.: Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla(R): a review of its use in the management of HIV infection. Drugs, 70: 2315-2338 (2010).
2. Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A. and Desta, Z.: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., 306: 287-300 (2003).
3. Ogburn, E. T., Jones, D. R., Masters, A. R., Xu, C., Guo, Y. and Desta, Z.: Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos., 38: 1218-1229 (2010).
4. Bélanger, A. S., Caron, P., Harvey, M., Zimmerman, P. A., Mehlotra, R. K. and Guillemette, C.: Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos., 37: 1793-1796 (2009).
5. Hariparsad, N., Nallani, S. C., Sane, R. S., Buckley, D. J., Buckley, A. R. and Desai, P. B.: Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J. Clin. Pharmacol., 44: 1273-1281 (2004).
6. Faucette, S. R., Zhang, T. C., Moore, R., Sueyoshi, T., Omiecinski, C. J., LeCluyse, E. L., Negishi, M. and Wang, H.: Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther., 320: 72-80 (2007).
7. Clarke, S. M., Mulcahy, F. M., Tjia, J., Reynolds, H. E., Gibbons, S. E., Barry, M. G. and Back, D. J.: The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol., 51: 213-217 (2001).
8. Gerber, J. G., Rosenkranz, S. L., Fichtenbaum, C. J., Vega, J. M., Yang, A., Alston, B. L., Brobst, S. W., Segal, Y. and Aberg, J. A.: Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr., 39: 307-312 (2005).
9. Michaud, V., Ogburn, E., Thong, N., Aregbe, A. O., Quigg, T. C., Flockhart, D. A. and Desta, Z.: Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers. Clin. Pharmacol. Ther., 91: 475-482 (2012).
10. Liu, P., Foster, G., LaBadie, R. R., Gutierrez, M. J. and Sharma, A.: Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. J. Clin. Pharmacol., 48: 73-84 (2008).
11. van Luin, M., Van der Ende, M. E., Richter, C., Visser, M., Faraj, D., Van der Ven, A., Gelinck, L., Kroon, F., Wit, F. W., Van Schaik, R. H., Kuks, P. F. and Burger, D. M.: Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ ritonavir. AIDS, 24: 1223-1226 (2010).
12. Boffito, M., Jackson, A., Lamorde, M., Back, D., Watson, V., Taylor, J., Waters, L., Asboe, D., Gazzard, B. and Pozniak, A.: Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. J. Acquir. Immune Defic. Syndr., 52: 222-227 (2009).
13. Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J. and Ruiz, N. M.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med., 341: 1865-1873 (1999).
14. Zhu, M., Kaul, S., Nandy, P., Grasela, D. M. and Pfister, M.: Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob. Agents Chemother., 53: 2346-2353 (2009).
15. Parikh, S., Ouedraogo, J. B., Goldstein, J. A., Rosenthal, P. J. and Kroetz, D. L.: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin. Pharmacol. Ther., 82: 197-203 (2007).
16. von Moltke, L. L., Greenblatt, D. J., Granda, B. W., Giancarlo, G. M., Duan, S. X., Daily, J. P., Harmatz, J. S. and Shader, R. I.: Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J. Clin. Pharmacol., 41: 85-91 (2001).
17. Hesse, L. M., von Moltke, L. L., Shader, R. I. and Greenblatt, D. J.: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab. Dispos., 29: 100-102 (2001).
18. Bumpus, N. N., Kent, U. M. and Hollenberg, P. F.: Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J. Pharmacol. Exp. Ther., 318: 345-351 (2006).
19. German, P., Greenhouse, B., Coates, C., Dorsey, G., Rosenthal, P. J., Charlebois, E., Lindegardh, N., Havlir, D. and Aweeka, F. T.: Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin. Infect. Dis., 44: 889-891 (2007).
20. Bonora, S., Lanzafame, M., D'Avolio, A., Trentini, L., Lattuada, E., Concia, E. and Di Perri, G.: Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin. Infect. Dis., 46: 146-147 (2008).
21. Robertson, S. M., Penzak, S. R., Lane, J., Pau, A. K. and Mican, J. M.: A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin. Infect. Dis., 41: e15-e18 (2005).
22. Jeong, S., Nguyen, P. D. and Desta, Z.: Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob. Agents Chemother., 53: 541-551 (2009).
23. Zhao, X. J., Jones, D. R., Wang, Y. H., Grimm, S. W. and Hall, S. D.: Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica, 32: 863-878 (2002).
24. Xu, C., Ogburn, E. T., Guo, Y. and Desta, Z.: Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 in vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates in vivo. Drug Metab. Dispos., 40: 717-725 (2012).
25. Lu, W. J., Xu, C., Pei, Z., Mayhoub, A. S., Cushman, M. and Flockhart, D. A.: The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res. Treat., 133: 99-109 (2012).
26. Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Gaman, E. A., Houston, J. B. and Tremaine, L. M.: The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther., 316: 336-348 (2006).
27. Shou, M., Hayashi, M., Pan, Y., Xu, Y., Morrissey, K., Xu, L. and Skiles, G. L.: Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. Drug Metab. Dispos., 36: 2355-2370 (2008).
28. Csajka, C., Marzolini, C., Fattinger, K., Decosterd, L. A., Fellay, J., Telenti, A., Biollaz, J. and Buclin, T.: Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther., 73: 20-30 (2003).
29. Walsky, R. L., Astuccio, A. V. and Obach, R. S.: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J. Clin. Pharmacol., 46: 1426-1438 (2006).
30. Obach, R. S., Walsky, R. L., Venkatakrishnan, K., Houston, J. B. and Tremaine, L. M.: In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin. Pharmacol. Ther., 78: 582-592 (2005).
31. Hulot, J. S., Bura, A., Villard, E., Azizi, M., Remones, V., Goyenvalle, C., Aiach, M., Lechat, P. and Gaussem, P.: Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108: 2244-2247 (2006).
32. Jeppesen, U., Rasmussen, B. B. and Brosen, K.: Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin. Pharmacol. Ther., 62: 279-286 (1997).
33. Carrington, H. C., Crowther, A. F., Davey, D. G., Levi, A. A. and Rose, F. L.: A metabolite of paludrine with high antimalarial activity. Nature, 168: 1080 (1951).
34. Lutz, J. D. and Isoherranen, N.: Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab. Dispos., 40: 159-168 (2012).
35. Lins, R., Broekhuysen, J., Necciari, J. and Deroubaix, X.: Pharmacokinetic profile of 14C-labeled clopidogrel. Semin. Thromb. Hemost., 25 Suppl 2: 29-33 (1999).
36. Tod, M., Goutelle, S. and Gagnieu, M. C.: Genotype-Based Quantitative Prediction of Drug Exposure for Drugs Metabolized by CYP2D6. Clin. Pharmacol. Ther., 90: 582-587 (2011).
37. Foti, R. S. and Wahlstrom, J. L.: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab. Dispos., 36: 523-528 (2008).
38. Metzger, I. F., Lu, J. B., Thong, N. and Desta, Z.: The antiretroviral drug efavirenz inhibits CYP1A2 activity in healthy volunteers. Abstract accepted for presentation at the Annual Meeting of American Society for Clinical Pharmacology and Therapeutics, March 6-9, Indianapolis, Indiana, USA. Clin. Pharmacol. Ther., 93(S1): S80 (2013).
39. Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M. and Lindley, C. M.: Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos., 28: 1222-1230 (2000).
40. Hesse, L. M., Venkatakrishnan, K., Court, M. H., von Moltke, L. L., Duan, S. X., Shader, R. I. and Greenblatt, D. J.: CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos., 28: 1176-1183 (2000).
41. Vandenbrink, B. M., Foti, R. S., Rock, D. A., Wienkers, L. C. and Wahlstrom, J. L.: Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition. Drug Metab. Dispos., 40: 47-53 (2012).
42. Oswald, S., Meyer zu Schwabedissen, H. E., Nassif, A., Modess, C., Desta, Z., Ogburn, E. T., Mostertz, J., Keiser, M., Jia, J., Hubeny, A., Ulrich, A., Runge, D., Marinova, M., Lutjohann, D., Kroemer, H. K. and Siegmund, W.: Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin. Pharmacol. Ther., 91: 506-513 (2012).
43. Kharasch, E. D., Whittington, D., Ensign, D., Hoffer, C., Bedynek, P. S., Campbell, S., Stubbert, K., Crafford, A., London, A. and Kim, T.: Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 91: 673-684 (2012).
44. Robertson, S. M., Maldarelli, F., Natarajan, V., Formentini, E., Alfaro, R. M. and Penzak, S. R.: Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J. Acquir. Immune Defic. Syndr., 49: 513-519 (2008).
45. Daily, E. B. and Aquilante, C. L.: Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics, 10: 1489-1510 (2009).
46. Kaspera, R., Naraharisetti, S. B., Evangelista, E. A., Marciante, K. D., Psaty, B. M. and Totah, R. A.: Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem. Pharmacol., 82: 681-691 (2011).
47. Lai, X. S., Yang, L. P., Li, X. T., Liu, J. P., Zhou, Z. W. and Zhou, S. F.: Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr. Drug Metab., 10: 1009-1047 (2009).
48. Totah, R. A. and Rettie, A. E.: Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther., 77: 341-352 (2005).
49. Rettie, A. E. and Jones, J. P.: Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol., 45: 477-494 (2005).
50. Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T. and Kurihara, A.: Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos., 38: 92-99 (2010).
51. Soyinka, J. O. and Onyeji, C. O.: Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur. J. Pharm. Sci., 39: 213-218 (2010).
52. Mouly, S., Lown, K. S., Kornhauser, D., Joseph, J. L., Fiske, W. D., Benedek, I. H. and Watkins, P. B.: Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther., 72: 1-9 (2002).
53. Cho, D. Y., Ogburn, E. T., Jones, D. and Desta, Z.: Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob. Agents Chemother., 55: 1504-1509 (2011).
54. di Iulio, J., Fayet, A., Arab-Alameddine, M., Rotger, M., Lubomirov, R., Cavassini, M., Furrer, H., Gunthard, H. F., Colombo, S., Csajka, C., Eap, C. B., Decosterd, L. A. and Telenti, A.: In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics, 19: 300-309 (2009).
55. Kwara, A., Lartey, M., Sagoe, K. W., Kenu, E. and Court, M. H.: CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS, 23: 2101-2106 (2009).
56. Li, X. Q., Bjorkman, A., Andersson, T. B., Ridderstrom, M. and Masimirembwa, C. M.: Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther., 300: 399-407 (2002).
57. Giancarlo, G. M., Venkatakrishnan, K., Granda, B. W., von Moltke, L. L. and Greenblatt, D. J.: Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur. J. Clin. Pharmacol., 57: 31-36 (2001).
58. Boulenc, X., Djebli, N., Shi, J., Perrin, L., Brian, W., Van Horn, R. and Hurbin, F.: Effects of Omeprazole and Genetic Polymorphism of CYP2C19 on the Clopidogrel Active Metabolite. Drug Metab. Dispos., 40: 187-197 (2012).